CRIS Current Research Information System

EVANGELISTI, CAMILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3519
EU - Europa 2794
AS - Asia 896
AF - Africa 138
SA - Sud America 9
OC - Oceania 3
Totale 7359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3510
GB - Regno Unito 821
SE - Svezia 561
CN - Cina 383
DE - Germania 342
IT - Italia 336
VN - Vietnam 268
UA - Ucraina 183
IN - India 161
IE - Irlanda 150
FR - Francia 118
RU - Federazione Russa 111
EE - Estonia 71
ZA - Sudafrica 68
JO - Giordania 46
TG - Togo 46
BE - Belgio 23
AT - Austria 18
IR - Iran 11
CH - Svizzera 10
HR - Croazia 10
CI - Costa d'Avorio 9
SC - Seychelles 9
CA - Canada 8
LB - Libano 7
BG - Bulgaria 6
FI - Finlandia 6
JP - Giappone 6
PT - Portogallo 6
CL - Cile 5
NG - Nigeria 4
NL - Olanda 4
AU - Australia 3
GR - Grecia 3
PK - Pakistan 3
PL - Polonia 3
TR - Turchia 3
BR - Brasile 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
ES - Italia 2
LA - Repubblica Popolare Democratica del Laos 2
SA - Arabia Saudita 2
DK - Danimarca 1
KR - Corea 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 7359
Salva come PNG Salva come JPEG
Città #
Southend 739
Fairfield 533
Chandler 357
Woodbridge 291
Houston 278
Wilmington 265
Ashburn 239
Seattle 223
Princeton 193
Ann Arbor 191
Cambridge 187
Dong Ket 159
Dublin 150
Bologna 130
Jacksonville 105
Nanjing 85
Westminster 80
Padova 75
Berlin 55
Amman 46
Lomé 46
Saint Petersburg 39
Redmond 38
San Diego 38
Shenyang 37
Jinan 36
Bremen 34
Beijing 32
Changsha 29
Nanchang 24
Brussels 21
Hebei 18
Norwalk 18
Boardman 17
Des Moines 17
Tianjin 17
Vienna 15
Medford 14
Dearborn 12
Falls Church 12
Haikou 12
Milan 12
Jiaxing 10
Ningbo 10
Olalla 10
Abidjan 9
Kuban 9
Mahé 9
Hangzhou 8
Taiyuan 8
Vittoria 8
Zhengzhou 8
Verona 7
Ferrara di Monte Baldo 6
Helsinki 6
San Venanzo 6
Sofia 6
Tokyo 6
Florence 5
Fuzhou 5
Guangzhou 5
Lausanne 5
Taizhou 5
Abeokuta 4
Chicago 4
Durham 4
Frankfurt Am Main 4
Kunming 4
Redwood City 4
Andover 3
Hefei 3
Kiev 3
London 3
Phoenix 3
Rize 3
Shanghai 3
Toronto 3
Urbino 3
Brembilla 2
Cedar Knolls 2
Changchun 2
Dallas 2
Fort Worth 2
Groningen 2
Lanzhou 2
Leawood 2
Lisbon 2
Locri 2
Misterbianco 2
Montreal 2
Moscow 2
Paris 2
Plauen 2
Provo 2
Puxian 2
Reggio Emilia 2
Rimini 2
Riyadh 2
San Francisco 2
Shahid Madani 2
Totale 5165
Salva come PNG Salva come JPEG
Nome #
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. 169
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. 152
Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. 144
Therapeutic targeting of CK2 in acute and chronic leukemias. 136
Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. 124
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. 120
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis? 117
Advances in Targeting Signal Transduction Pathways. 116
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 115
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 112
Cutting edge: the role of mTOR signaling in laminopathies. 109
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. 108
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 107
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 107
Nuclear inositol lipid metabolism: more than just second messenger generation? 103
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. 101
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias 100
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. 99
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 99
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. 98
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 98
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 97
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 96
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 95
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update. 94
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance 93
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 93
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 93
Nuclear phosphoinositides and their roles in cell biology and disease. 92
GSK-3β: a key regulator of breast cancer drug resistance 92
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 92
Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. 92
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 91
Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulations of PC12 cells 90
The emerging multiple roles of nuclear Akt. 90
Nuclear protein kinase C 89
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the pro-apoptotic NF-κB. 89
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia 89
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 88
TIS2/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest 87
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 86
null 86
Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. 85
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. 85
Therapeutic targeting of polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblstic leukemia. 84
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. 84
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion 84
Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. 83
The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML) 82
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance 82
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 82
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells. 81
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. 80
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. 78
Nuclear diacylglycerol kinase-{zeta} is a negative regulator of cell cycle progression in C2C12 mouse myoblasts 76
New advances in targeting aberrant signaling pathways in T-cell Acute Lymphoblastic Leukemia. 76
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 76
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. 74
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 73
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. 71
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 71
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 70
Intranuclear 3'-phosphoinositide metabolism and apoptosis protection in PC12 cells 69
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy 69
DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. 69
null 69
New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways. 67
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis. 67
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 67
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 66
Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance 66
Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks 66
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 66
null 62
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. 61
Morphological and biochemical patterns in skeletal muscle apoptosis. 60
PI3K isoforms inhibition associated with anti BCR-ABL1 drugs shows in vitro increased anti-leukemic activity in B-pre acute lymphoblastic leukemia. 60
Nuclear expression of diacylglycerol kinases: possible involvement in DNA replication. 57
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 56
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. 55
null 53
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 48
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. 46
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. 46
null 45
GSK-3: a multifaceted player in acute leukemias. 45
Elevated tgf b2 serum levels in emery-dreifuss muscular dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 40
The role played by Wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia. 38
The PI3K/Akt/mTOR Pathway 34
The unfolded protein response: a novel therapeutic target in acute leukemias. 31
Nuclear phosphoinositide specific phospholipase C (PI-PLC)-ss1: a central intermediary in nuclear lipid-dependent signal transduction 27
Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders 22
Pathobiology and therapeutic relevance of GSK-3 in chronic hematological malignancies. 20
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 19
Totale 7591
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11582
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018151 0000 00 00 001465
2018/2019579 2173171 1375 4013 56873099
2019/20202333 3296225147 214250 281275 35115383163
2020/20211036 216982627 2439 1275 895960311
2021/20221894 20038135134 151103 36133 51287336290
2022/20231475 17321581244 119130 90110 313000
Totale 7591